SHORT MINI-FUTURE - GILEAD SCIENCES | Market Closed - Börse Stuttgart 15:37:42 2024-05-24 EDT | ||
| 4.05 EUR | +1.76% |
|
| Current month | -2.17% | ||
| 1 month | +2.53% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
GILEAD SCIENCES, INC.
Latest news about GILEAD SCIENCES, INC.
More news
| Date | Price | Change |
|---|---|---|
| 24-05-24 | 4.05 | +1.76% |
| 24-05-23 | 3.98 | +2.84% |
| 24-05-22 | 3.87 | +0.26% |
| 24-05-21 | 3.86 | +1.58% |
| 24-05-20 | 3.8 | -1.04% |
Delayed Quote Börse Stuttgart
Last update May 24, 2024 at 03:37 pm
More quotesStatic data
| Product type | Knock-Out with Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | GILEAD SCIENCES, INC. |
| Issuer | 
Vontobel
|
| WKN | VZ6XG6 |
| ISIN | DE000VZ6XG64 |
| Date issued | 2014-10-10 |
| Strike | 109.2 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 4.13 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 7.31 € |
|---|---|
| Lowest since issue | 2 € |
Company Profile
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows:
- sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV);
- other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products.
Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Sector
-
Consensus: Gilead Sciences, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
65.68
USD
Average target price
82.77
USD
Spread / Average Target
+26.03%
- Stock Market
- Certificates
- Certificat
